Business
SAFE-HEMO-CAR-T Effective against AML in vitro
SAFE-HEMO-CAR-T Effective against AML in vitro.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1571B\n Hemogenyx Pharmaceuticals PLC\n 06 October 2020\n \n \n \n 6 October 2020\n \n \n Hemogenyx Pharmaceuticals plc \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n CAR-T Cells with a Safety Switch are Effective against AML in vitro\n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the following update on its activities.\n \n As previously announced, Hemogenyx Pharmaceuticals' CDX bi-specific antibody has the potential to treat Acute Myeloid Leukemia (\"AML\") directly as well as to provide a benign conditioning regimen for blood stem cell replacement therapy. The Company has now carried out extensive work developing treatments for AML and has to date obtained encouraging results.\n \n As announced on 20 February 2020, the Company has constructed and successfully tested in vivo Chimeric Antigen Receptor (\"CAR\") programmed T cells (\"HEMO-CAR-T\") for the potential treatment of AML. HEMO-CAR was constructed using the Company's proprietary humanized monoclonal antibody against a target on the surface of AML cells.\n \n It was also announced that the Company was engaging in additional engineering of HEMO-CAR-T cells to increase their safety and versatility. The Company has now introduced and successfully in vitro tested a safety switch within the HEMO-CAR. The aim of this safety switch is to modulate the activity of HEMO-CAR-T cells and to turn them into a \"controllable drug\" - SAFE-HEMO-CAR-T. The purpose of these efforts is to dramatically improve the safety and potential versatility of HEMO-CAR-T cells for the treatment of AML and/or conditioning of bone marrow transplants, as well as a number of additional potential indications.\n \n Following the successful completion of these in vitro tests, in vivo tests of the efficacy of SAFE-HEMO-CAR-T against AML are being conducted using a model of AML established on the background of Advanced peripheral blood Hematopoietic Chimera (ApbHC) - humanized mice developed by Immugenyx, LLC, a subsidiary of Hemogenyx Pharmaceuticals. If these in vivo tests are successful, the Company will discuss its findings with its partners under the Sponsored Research Agreement with the University of Penn...